RecruitingNCT06392217
clinIcal Efficacy and Safety of Incadronate in Breast Cancer With Bone Metastases
Real-world Study of Incadronate in Breast Cancer Patients With Metastatic Bone Disease: clinIcal Efficacy and Safety
Sponsor
Fudan University
Enrollment
500 participants
Start Date
Mar 12, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
This is a real-world study to explore the efficacy and safety of incadronate in the treatment of breast cancer patients with bone metastases.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This study is testing the effectiveness and safety of a drug called incadronate — a type of bisphosphonate that helps protect bones — in people with breast cancer that has spread to the bones. Bone metastases can cause pain, fractures, and other serious complications.
**You may be eligible if...**
- You are 18 or older
- You have been diagnosed with breast cancer that has spread to the bones (confirmed by imaging or biopsy)
- You are in generally good health (ECOG score of 3 or lower)
- You have no serious heart disease
- You are willing to use contraception throughout the study and for 6 months after
**You may NOT be eligible if...**
- You are pregnant or breastfeeding
- You have another active serious disease or infection
- You have had another type of cancer in the past 5 years (except certain curable cancers)
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06392217
Related Trials
Utility of a Mobile Application for Young Women With Breast Cancer
NCT070090931 location
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
NCT0710010645 locations
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
NCT028307241 location
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
NCT07085767150 locations
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
NCT0740580145 locations